NasdaqGM - Nasdaq Real Time Price USD
Gain Therapeutics, Inc. (GANX)
1.9200
+0.0350
+(1.86%)
At close: June 6 at 4:00:01 PM EDT
1.9999
+0.08
+(4.16%)
After hours: June 6 at 7:56:18 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 3 | 4 |
| Avg. Estimate | -0.17 | -0.14 | -0.67 | -0.79 |
| Low Estimate | -0.18 | -0.18 | -0.71 | -1.41 |
| High Estimate | -0.16 | -0.09 | -0.59 | -0.35 |
| Year Ago EPS | -0.42 | -0.17 | -0.89 | -0.67 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 5 |
| Avg. Estimate | -- | -- | -- | 40k |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 200k |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.22 | -0.21 | -0.19 | -0.17 |
| EPS Actual | -0.42 | -0.17 | -0.08 | -0.16 |
| Difference | -0.2 | 0.04 | 0.11 | 0.01 |
| Surprise % | -90.91% | 20.31% | 57.33% | 4.00% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.17 | -0.14 | -0.67 | -0.79 |
| 7 Days Ago | -0.19 | -0.15 | -0.66 | -0.98 |
| 30 Days Ago | -0.19 | -0.15 | -0.66 | -0.98 |
| 60 Days Ago | -0.17 | -0.15 | -0.79 | -1.41 |
| 90 Days Ago | -0.17 | -0.15 | -0.79 | -1.41 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | 2 | -- |
| Up Last 30 Days | 2 | 2 | 2 | -- |
| Down Last 7 Days | 1 | 1 | -- | 1 |
| Down Last 30 Days | 1 | 1 | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| GANX | 59.52% | 14.71% | 25.09% | -18.50% |
| S&P 500 | 13.13% | 2.48% | 7.55% | 14.01% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/19/2025 |
| Maintains | Chardan Capital: Buy to Buy | 3/28/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/17/2025 |
| Initiated | Scotiabank: Sector Outperform | 3/7/2025 |
| Maintains | Roth MKM: Buy to Buy | 12/24/2024 |
| Initiated | Roth MKM: Buy | 12/5/2024 |
Related Tickers
COYA Coya Therapeutics, Inc.
5.88
+3.16%
INMB INmune Bio, Inc.
7.62
+3.67%
CHRO Channel Therapeutics Corporation
1.1397
+6.02%
PHGE BiomX Inc.
0.4691
-4.27%
NRSN NeuroSense Therapeutics Ltd.
1.7900
+4.07%
CUE Cue Biopharma, Inc.
0.6410
+1.73%
ABEO Abeona Therapeutics Inc.
6.74
+4.01%
ACTU Actuate Therapeutics, Inc. Common stock
8.96
-1.43%
APS.TO Aptose Biosciences Inc.
2.4500
+5.15%
ZVSA ZyVersa Therapeutics, Inc.
0.6549
+1.50%